The present invention relates to a pharmaceutical combination comprising a phosphatidylinositol- 3-kinase (PI3K) inhibitor compound which is a 2-carboxamide cycloamino urea derivative or a pharmaceutically acceptable salt thereof and at least one mammalian target of rapamycin (mTOR) inhibitor or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising such a combination; and the uses of such a combination in the treatment proliferative diseases, more specifically of mammalian target of rapamycin (mTOR) kinase dependent diseases.本發明係關於一種醫藥組合,包括磷脂醯肌醇-3-激酶(PI3K)抑制劑化合物,其為2-甲醯胺環胺基脲衍生物或其醫藥上可接受的鹽,及至少一種哺乳動物雷帕黴素(rapa-mycin)靶(mTOR)抑制劑或其醫藥上可接受的鹽;一種包括該組合之醫藥組合物;及該組合於治療增生性疾病(更特定為哺乳動物雷帕黴素靶(mTOR)激酶依賴性疾病)之用途。